NCT06901518View on ClinicalTrials.gov

The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

June 30, 2024

Study Completion Date

November 30, 2024

Conditions
Post-Traumatic Headache
Interventions
DRUG

Galcanezumab-Gnlm

Subcutaneous injection

Trial Locations (1)

12208

Albany Medical Center, Albany

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Albany Medical College

OTHER